Fibrillary glomerulonephritis associated with crescents as a therapeutic challenge

被引:8
作者
Blume, C
Ivens, K
May, P
Helmchen, U
Jehle, PM
Riedel, M
Keller, F
Grabensee, B
机构
[1] Univ Dusseldorf, Klin Nephrol & Rheumatol, D-40225 Dusseldorf, Germany
[2] Univ Hamburg, Krankenhaus Eppendorf, Inst Pathol, D-2000 Hamburg, Germany
[3] Univ Ulm Klinikum, Innere Med Abt 2, Sekt Nephrol, Ulm, Germany
关键词
crescentic glomerulonephritis; fibrillary glomerulonephritis (FG); immunosuppressive treatment; cyclophosphamide; severe nephrotic syndrome; severe limitation of renal function;
D O I
10.1053/ajkd.2002.34548
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Most cases of fibrillary glomerulonephritis (FG) terminate in end-stage renal disease within a few years. We report on two female patients (41 and 50 years old) with the diagnosis of FG associated with crescentic glomerulonephritis, a combination found in 20% to 25% of cases of FG. A broad spectrum of infectious disease and systemic Immunologic disorders could be ruled out by specific assays. Both patients had severely impaired renal function, nephrotic syndrome, and hypertension. Based on the biopsy finding with necrotizing FG, treatment was started with corticosteroids and cyclophosphamide. In both patients, renal function recovered markedly within 6 months of treatment, in one case remaining stable for 3.5 years. Whether or not cyclophosphamide treatment changed the course of the FG itself or counteracted the acute crescentic process cannot be determined from these two patients. Based on these promising preliminary findings and the poor prognosis of FG, however, we recommend cyclophosphamide treatment of patients with FG and additional crescentic glomerulonephritis. For a systematic evaluation of the therapeutic options in FG, a multicenter clinical trial should be conducted. (C) 2002 by the National Kidney Foundation, Inc.
引用
收藏
页码:420 / 425
页数:6
相关论文
共 16 条
[1]  
ADEY DB, 1995, J AM SOC NEPHROL, V6, P171
[3]   Fibrillary glomerulopathy [J].
Brady, HR ;
Harrington, JT ;
Garrett, P ;
Donohoe, J ;
O'Meara, Y ;
Keogh, BA ;
Fitzpatrick, JM ;
Sheahan, K ;
Dorman, A ;
Gaffney, E ;
Murnaghan, D ;
Cottell, DC ;
Mellotte, G ;
Muldowney, FP .
KIDNEY INTERNATIONAL, 1998, 53 (05) :1421-1429
[4]  
CALLS GJ, 1995, CLIN NEPHROL, V43, P180
[5]  
D'AGATI V, 1991, Journal of the American Society of Nephrology, V2, P591
[6]   A 51-year-old woman with nephrotic syndrome, hematuria, and renal insufficiency [J].
Fogo, A ;
Horn, RG .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1997, 29 (05) :806-810
[7]   CLINICAL AND PATHOLOGICAL FEATURES OF FIBRILLARY GLOMERULONEPHRITIS [J].
ISKANDAR, SS ;
FALK, RJ ;
JENNETTE, JC .
KIDNEY INTERNATIONAL, 1992, 42 (06) :1401-1407
[8]   THE FIBRILLARY GLOMERULOPATHIES [J].
KORBET, SM ;
SCHWARTZ, MM ;
LEWIS, EJ .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1994, 23 (05) :751-765
[9]   PULMONARY HEMORRHAGE IN A PATIENT WITH FIBRILLARY GLOMERULONEPHRITIS [J].
MASSON, RG ;
RENNKE, HG ;
GOTTLIEB, MN .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (01) :36-39
[10]   Rapidly progressive renal failure with nephrotic syndrome in a patient with type 2 diabetes mellitus: The differential of fibrillary deposits [J].
Ovuworie, C ;
Volmar, K ;
Charney, D ;
Kravet, S ;
Racusen, L .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2000, 35 (01) :173-177